In the high-stakes world of medical research, few things are as thrilling—and alarming—as discovering that a promising breakthrough might be built on shaky ground. Imagine a study claiming that stem cell therapy could slash the risk of heart failure, only for eagle-eyed investigators to uncover glaring inconsistencies in the data. That's the heart of the controversy surrounding a recent paper in The BMJ, and it's the kind of story that keeps science enthusiasts and skeptics alike glued to the details. But here's where it gets really intriguing: what if the flaws go beyond simple errors and touch on deeper issues of trust in clinical trials? Let's dive in and unpack this step by step.
The BMJ, a prestigious medical journal, has taken the serious step of issuing an expression of concern for an article that boldly asserted stem cell treatments could lower the chances of heart failure. This decision follows intense scrutiny from online sleuths and fellow scientists who spotted a "complete mismatch" between the study's reported data and the actual numbers presented.
As I shared in a previous update (https://retractionwatch.com/2025/11/06/sleuths-flag-complete-mismatch-in-data-of-bmj-stem-cell-study/), the paper, published on October 29, detailed the outcomes of a phase III clinical trial conducted in Shiraz, Iran. For beginners, a phase III trial is like the final major hurdle before a treatment gets approved—it involves thousands of participants to confirm safety and effectiveness in real-world conditions. Critics wasted no time flagging irregularities on PubPeer, a platform where researchers post comments on published papers. Psychologist Nick Brown was among the first, highlighting a "curious repeating pattern of records in the dataset" that appeared every 101 entries, which raised eyebrows about whether the data was authentic or manipulated.
In the expression of concern (https://www.bmj.com/content/391/bmj-2024-083382) released today, The BMJ openly addressed problems evident in the supporting data. These included irregularities in the data itself, inconsistencies in the age criteria versus the actual ages of participants, and undisclosed conflicts of interest that weren't revealed upfront. Conflicts of interest in research occur when authors have personal stakes that might influence their objectivity, like financial ties to companies or charities benefiting from the study.
Dorothy Bishop (https://retractionwatch.com/2015/11/24/improving-reproducibility-what-can-funders-do-guest-post-by-dorothy-bishop/), a professor of developmental neuropsychology at Oxford University, was the trailblazer in spotting these flaws. She pointed out that the study claimed to include only patients under 65 years old, but the shared dataset (https://figshare.com/articles/dataset/bPREVENT-TAHA8studyDatasetPreventionofAcuteMyocardialInfarction-InducedHeartFailurebyIntracoronaryInfusionofMesenchymalStemCellsAPhaseIIIRandomizedClinicalTrialb/29375153/2?file=55664687) showed 127 participants over that age—a stark "complete mismatch," as she described it to us. Moreover, the authors only provided this data to the journal and reviewers after the paper had already passed two rounds of peer review (https://www.bmj.com/content/391/bmj-2024-083382/peer-review), which is a common process where experts evaluate the manuscript for quality and validity before publication.
On PubPeer, Bishop also raised alarms about potential conflicts of interest. She noted that co-author Anthony Mathur (https://www.qmul.ac.uk/whri/people/academic-staff/items/mathuranthony.html), a researcher at Queen Mary University of London, holds shares (https://find-and-update.company-information.service.gov.uk/company/10282577/officers) and serves as a trustee for the Heart Cells Foundation, a charity that operates a unit (https://www.heartcellsfoundation.com/compassionate-centre/) dedicated to delivering stem cell therapies for heart patients. This connection could imply a vested interest in promoting positive results for stem cell treatments.
The notice from The BMJ bluntly states that the editors believe the trial might have violated standard ethical practices, casting doubt on the reliability of its findings. The journal intends to conduct a thorough investigation and is reviewing an "auditable replacement dataset" submitted by the authors. Most of the research team, including lead author Armin Attar (https://www.linkedin.com/in/armin-attar-26ba11173/?originalSubdomain=ir), are affiliated with Shiraz University of Medical Sciences.
Following our initial report, more issues surfaced (https://pubpeer.com/publications/C08779C45DB6E407DFAC85583BE9C4#1) from vigilant observers. Gideon Meyerowitz-Katz (https://retractionwatch.com/?s=Gideon+Meyerowitz-Katz), a research fellow at the University of Wollongong in Australia, identified "oddities" such as nearly half of the heart rate readings being evenly divisible by five—a statistical quirk that could suggest fabricated data. He also observed an unusual distribution in patient temperatures: out of 311 records, 42 were exactly 36.2 degrees Celsius, which is an unexpectedly precise and recurring figure.
Retractions from The BMJ are exceedingly rare, adding weight to this case. The journal's first retraction happened in 1989, and only 12 articles total have been pulled since then (https://retractiondatabase.org/RetractionSearch.aspx?%3d1%26jou%3dBMJ%253a%2bBritish%2bMedical%2bJournal), according to the Retraction Watch Database.
And this is the part most people miss: while data irregularities can stem from honest mistakes, the pattern here points to potential fabrication, which undermines the entire foundation of evidence-based medicine. Stem cell research holds immense promise for treating heart conditions, but scandals like this fuel debates about whether hope is being sold too quickly without rigorous checks. Do you think journals should impose stricter pre-publication data audits to prevent such controversies? Or is the current peer review system sufficient, despite its flaws? Share your thoughts in the comments—do you side with the critics, or believe the authors deserve a chance to explain? What would you do if you were in the editors' shoes? Your perspectives could spark a lively discussion!
